Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.
Aldehydes, including acetaldehyde and formaldehyde, can cause DNA damage by inducing DNA interstrand crosslinks, which cause damage to hematopoietic stem cells, leading to bone marrow failure and cancer in people with Fanconi anemia (FA). Exposure to aldehydes is inevitable and...
Announcements
Pilot Study on Metformin A National Institutes of Health program project grant on Fanconi anemia (FA) led by Dr. Markus Grompe at Oregon Health & Science University identified that metformin (a drug approved by the FDA to treat type II...
Announcements
Fanconi anemia (FA) is a hereditary disorder with a high predisposition to cancer, especially leukemia and squamous cell carcinoma (SCC). Head and neck squamous cell carcinoma (HNSCC) is the most common SCC diagnosed in people with FA. Diagnosis typically occurs...
Announcements
The David B. Frohnmayer Early Investigator Award was inaugurated in 2015, months after FARF co-founder Dave Frohnmayer passed away. One of his most salient leadership traits was his ability to recognize talent in others and inspire them to solve important...
Announcements
Mutations in 23 Fanconi anemia (FA) genes cause defects in DNA repair, which leads to chromosome instability, bone marrow failure, malformations, and susceptibility to cancer. The most well-described role of FA genes in DNA repair is known as the “canonical”...
Announcements
One of FARF’s guiding principles is to gather researchers and clinicians in the FA community every year to share updates in research and care. In September 2019, we held the 31st Fanconi Anemia Scientific Symposium in Chicago, Ill. Forty-four presenters...
Stories
